{"url_path":"/sec/tgtx/8-k/2026-06-12/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1001316/0001437749-26-020491-index.html","accession_number":"0001437749-26-020491","cik":"0001001316","ticker":"TGTX","issuer_name":"TG THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001316/0001437749-26-020491-index.html","primary_entity_key":"0001001316","primary_entity_name":"TG THERAPEUTICS, INC."},"word_count":342,"has_tables":true,"body_markdown":"**Item 5.07.**\n\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn Thursday, June 11, 2026, at 9:30 a.m. Eastern Time, by means of an online meeting platform, TG Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting. Stockholders representing 113,003,414, or 73.81%, of the 153,093,879 outstanding shares were present in person or by proxy, constituting a quorum under applicable law. Proxies were solicited by the Company pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “SEC”). Each of the proposals below are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting, filed with the SEC on April 30, 2026. At the 2026 Annual Meeting, all of the proposals were approved except for proposal 3.\n\n \n\nThe results are as follows:\n\n \n\n**Proposal 1**\n\n \n\nThe votes with respect to the election of the six directors to hold office until the 2027 annual meeting were as follows:\n\n**Director**\n\n**Votes For**\n\n**% Voted For**\n\n**Votes Withheld**\n\n**% Voted Withheld**\n\n**Broker Non-Votes**\n\nMichael S. Weiss\n\n72,172,630\n\n88.63%\n\n9,260,279\n\n11.37%\n\n31,570,505\n\nLaurence N. Charney\n\n68,135,448\n\n83.67%\n\n13,297,461\n\n16.33%\n\n31,570,505\n\nYann Echelard\n\n64,110,661\n\n78.73%\n\n17,322,248\n\n21.27%\n\n31,570,505\n\nKenneth Hoberman\n\n53,354,717\n\n65.52%\n\n28,078,192\n\n34.48%\n\n31,570,505\n\nDaniel Hume\n\n63,979,535\n\n78.57%\n\n17,453,374\n\n21.43%\n\n31,570,505\n\nSagar Lonial, MD\n\n44,666,544\n\n54.85%\n\n36,766,365\n\n45.15%\n\n31,570,505\n\n \n\n \n\n**Proposal 2**\n\n \n\nThe vote with respect to the ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows:\n\n \n\n**Total Votes For**\n\n**Total Votes Against**\n\n**Abstentions**\n\n**Broker Non-Votes**\n\n112,329,330\n\n531,758\n\n142,326\n\n--\n\n \n\n \n\n**Proposal 3**\n\n \n\nThe advisory vote to approve the compensation of the Company’s named executive officers was as follows:\n\n \n\n**Total Votes For**\n\n**Total Votes Against**\n\n**Abstentions**\n\n**Broker Non-Votes**\n\n31,905,837\n\n48,858,169\n\n668,903\n\n31,570,505\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nTG THERAPEUTICS, INC.\n\n \n\n \n(Registrant)\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: June 12, 2026\n\nBy:\n\n/s/ Sean A. Power\n\n \n\n \nName:\nSean A. Power\n \n\n \nTitle:\nChief Financial Officer"}